BioStock: Ultimovacs initiates fourth phase II trial with UV1

Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth phase II trial with universal vaccine UV1. The combination study, aimed at head and neck cancer patients indicated to receive checkpoint inhibitor pembrolizumab, will be conducted at 10 sites across Germany and led by renowned principal investigator Prof. Mascha Binder, M.D.

Read the full article at biostock.se:

https://www.biostock.se/en/ultimovacs-initiates-fourth-phase-ii-trial-with-uv1/

This is a press release from BioStock - Connecting Innovation & Capital.